Efficacy and safety of Hou Gu Mi Xi for peptic ulcer diseases: Study protocol for a randomized controlled trial

Xiaofan Chen, Dongmei Yan, Jianhe Fang, Wenjun Liu, Heyun Nie, Nonghua Lv, Nian Fang, Jinhua Gong, Jianwei Yu, Yiping Jiang, Zhijun Liu, Huihu Gan, Ying Fu, Deping Yang, Yan Xiong, Dunju Liu, Ming Chen, Yanping Wang, Yang Wang, Xin Sun, Xu Zhou, Weifeng Zhu, Xiaofan Chen, Dongmei Yan, Jianhe Fang, Wenjun Liu, Heyun Nie, Nonghua Lv, Nian Fang, Jinhua Gong, Jianwei Yu, Yiping Jiang, Zhijun Liu, Huihu Gan, Ying Fu, Deping Yang, Yan Xiong, Dunju Liu, Ming Chen, Yanping Wang, Yang Wang, Xin Sun, Xu Zhou, Weifeng Zhu

Abstract

Background: Peptic ulcer disease (PUD) is a major burden worldwide. Several challenges remain with standard Western treatment of PUD, such as persistent weakness, fatigue, and relapse. A dietary traditional Chinese medicine (TCM) formula, Hou Gu Mi Xi (HGMX), has been developed as a complementary treatment for PUD.

Aims: This multicenter, double-blind, randomized controlled trial will assess efficacy and safety of HGMX in patients with PUD.

Methods: Three hundred sixty eligible patients will be assigned to receive HGMX, placebo, HGMX + rabeprazole or placebo + rabeprazole for 4 weeks after 2 weeks of standard Western treatment. This first step, with a 2 × 2 factorial design, will focus on assessing the main and interaction effects of HGMX and rabeprazole on ulcer healing. Then, rabeprazole will be stopped, and HGMX will be continued for up to 1 year. The second step, with a placebo-controlled design, will compare the long-term effects of HGMX and placebo. Extended follow-up with no treatment will continue for up to 2 years. Independent and paired t tests, Pearson χ test and the rank-sum test will be used to compare between-group differences. The P value will be adjusted using the O'Brien & Fleming method for multiple comparisons.

Expected outcomes: The primary outcomes are total efficacy rate of PUD treatment, quality of ulcer healing, and changes in spleen qi deficiency symptoms. The secondary outcomes include ulcer area, PUD recurrence, Helicobacter pylori eradication rate, gastric function, body weight, and body mass index. Adverse events (AEs), severe AEs, treatment-related AEs, and withdrawal owing to AEs will be recorded to assess treatment safety.

Discussion: The trial results will provide high-quality evidence for HGMX, as a complementary therapy, for the long-term management of PUD and will be valuable for the development of related guidelines and regulations.

Trial registration: The protocol of this trial was approved in all research hospitals and was registered in ClinicalTrials.gov at October 25, 2017(No. NCT03320538).

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Study flow diagram. HGMX = Hou Gu Mi Xi.

References

    1. Asali AM, Alghamdi MA, Fallatah SA, et al. Risk factors leading to peptic ulcer disease: systematic review in literature. Int J Community Med Public Health 2018;5:4617–24.
    1. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009;29:938–46.
    1. Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010;105:2570–7.
    1. Satoh K, Yoshino J, Akamatsu T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol 2016;51:177–94.
    1. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728–38.
    1. Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician 2007;76:1005–12.
    1. Wu Y, Fan Y, Jiang Y, et al. Analysis of risk factors associated with precancerous lesion of gastric cancer in patients from eastern China: a comparative study. J Cancer Res Ther 2013;9:205–9.
    1. Hu ZH, Shi AM, Hu DM, et al. Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials. Saudi J Gastroenterol 2017;23:11–9.
    1. Barkun A, Leontiadis G. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med 2010;123:358–66. e352.
    1. Lau JY, Sung J, Hill C, et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 2011;84:102–13.
    1. Huang CY, Lai WY, Sun MF, et al. Prescription patterns of traditional Chinese medicine for peptic ulcer disease in Taiwan: A nationwide population-based study. J Ethnopharmacol 2015;176:311–20.
    1. Jiang GR, Ge HN, Liang GQ, et al. Therapeutic and recurrence-preventing effects of Qi-Replenishing and Blood-Activating Formula in rats with acetic acid-induced gastric ulcer. Asian Pac J Trop Med 2016;9:81–5.
    1. Ma LS, Guo TM. Combination of traditional Chinese medicine and Western medicine in the treatment of resistant peptic ulcer. Chin Med J (Engl) 1994;107:554–6.
    1. Chen X, Hu L, Wu H, et al. Anti-Helicobacter pylori and anti-inflammatory effects and constituent analysis of modified Xiaochaihutang for the treatment of chronic gastritis and gastric ulcer. Evid Based Complement Alternat Med 2018;2018:6810369.
    1. Wang S, Ni Y, Liu J, et al. Protective effects of Weilikang decoction on gastric ulcers and possible mechanisms. J Nat Med 2016;70:391–403.
    1. Yan B, Shi J, Xiu LJ, et al. Xiaotan Tongfu granules contribute to the prevention of stress ulcers. World J Gastroenterol 2013;19:5473–84.
    1. Yi SX, Yang RD, Yan J, et al. Effect of electro-acupuncture at Foot-Yangming Meridian on somatostatin and expression of somatostatin receptor genes in rabbits with gastric ulcer. World J Gastroenterol 2006;12:1761–5.
    1. Huang X, Sun X, Yu X, et al. Efficacy and safety of Sijunzi decoction for peptic ulcers: a systematic review and meta-analysis (in Chinese). J Trad Chin Med Sci 2018;5:237–54.
    1. Zheng X. Clinical guideline of new drugs for traditional Chinese medicine (in Chinese). Beijing: Medicine Science and Technology Press of China; 1993.
    1. Ji HJ, Kang N, Chen T, et al. Shen-ling-bai-zhu-san, a spleen-tonifying Chinese herbal formula, alleviates lactose-induced chronic diarrhea in rats. J Ethnopharmacol 2019;231:355–62.
    1. Chen M, Xie S, Dai W, et al. Applications and research progresses of Shenling Baizhu decoction in digestive system diseases (in Chinese). J Liaoning Univ Trad Chin Med 2018;20:164–6.
    1. Kaneko E, Hoshihara Y, Sakaki N, et al. Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor. J Gastroenterol 2000;35:824–31.
    1. Pan SA, Liao CH, Lien GS, et al. Histological maturity of healed duodenal ulcers and ulcer recurrence after treatment with colloidal bismuth subcitrate or cimetidine. Gastroenterology 1991;101:1187–91.
    1. Zhong B. How to calculate sample size in randomized controlled trial? J Thorac Dis 2009;1:51–4.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj